IP Library Granted Patent US 10,835,612
Granted Patent B2
US 10,835,612 · App. 15/671,809 · Granted Nov 17, 2020

Lipids and compositions for the delivery of therapeutics

Inventors: Muthiah Manoharan (Cambridge, MA); Kallanthottathil G. Rajeev (Cambridge, MA); David Butler (Medford, MA); Jayaprakash K. Nair (Cambridge, MA); Muthusamy Jayaraman (Cambridge, MA); Laxman Eltepu (Cambridge, MA)
Assignee: ARBUTUS BIOPHARMA CORPORATION
A61K47/44A61K9/1272A61K31/7088A61K31/713A61K39/00A61K39/39A61K47/10A61K47/18A61K47/20A61K47/28C07C229/08C07C229/30C07C237/16C07C251/38C07C251/78C07C271/12C07C271/20C07C323/25C07D203/10C07D317/28C07D317/44C07D317/46C07D317/72C07D319/06C07D405/12C07D491/056C07D491/113C12N15/111C12N15/113A61K2039/55555A61K2039/55561C12N2310/14C12N2310/3515C12N2320/32Y02A50/464
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,835,612
App. No.
15/671,809
Granted
Nov 17, 2020
Kind
B2
Abstract

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures:

Claims (28)

1. A lipid having the structure of formula I

or a salt or isomer thereof, wherein:

R 1 and R 2 are each independently for each occurrence optionally substituted C 10 -C 30 alkoxy, optionally substituted C 10 -C 30 alkenyl, optionally substituted C 10 -C 30 alkenyloxy, optionally substituted C 10 -C 30 alkynyl, optionally substituted C 10 -C 30 alkynyloxy, or optionally substituted C 10 -C 30 acyl;

R 3 is independently for each occurrence H, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted alkylheterocycle, optionally substituted heterocyclealkyl, optionally substituted alkylphosphate, optionally substituted phosphoalkyl, optionally substituted alkylphosphorothioate, optionally substituted phosphorothioalkyl, optionally substituted alkylphosphorodithioate, optionally substituted phosphorodithioalkyl, optionally substituted alkylphosphonate, optionally substituted phosphonoalkyl, optionally substituted amino, optionally substituted alkylamino, optionally substituted di(alkyl)amino, optionally substituted aminoalkyl, optionally substituted alkylaminoalkyl, optionally substituted di(alkyl)aminoalkyl, optionally substituted hydroxyalkyl, optionally substituted polyethylene glycol, optionally substituted mPEG, optionally substituted heteroaryl, or optionally substituted heterocycle;

X and Y are each independently —O—, —S—, alkylene, —N(Q)-, —C(O)—, —O(CO), —OC(O)N(Q)-, —N(Q)C(O)O—, —C(O)O, —OC(O)O—, —OS(O)(Q 2 )O—, or —OP(O)(Q 2 )O—;

Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalkyl, ω-phosphoalkyl, or ω-thiophosphoalkyl;

Q 2 is independently for each occurrence O, S, N(Q)(Q), alkyl or alkoxy;

A 1 , and A 2 are each independently —O—, —S—, —CH 2 —, —CHR 5 —, —CR 5 R 5 —, —CHF— or —CF 2 —;

R 5 is H, halo, cyano, hydroxy, amino, optionally substituted alkyl, optionally substituted alkoxy, or optionally substituted cycloalkyl;

Z is N, or C(R 3 ); and

m and n are each independently 0 to 5, where m and n taken together result in a 3, 4, 5, 6, 7 or 8 member ring.

2. A lipid selected from the group consisting of:

and salts and isomers thereof.

3. A lipid particle comprising a lipid of claim 1 .

4. The lipid particle of claim 3 , further comprising a therapeutic agent.

5. The lipid particle of claim 4 , wherein the therapeutic agent is a nucleic acid.

6. The lipid particle of claim 5 , wherein the nucleic acid is selected from the group consisting of an siRNA, an antisense oligonucleotide, a microRNA, an antagomir, an aptamer, and a ribozyme.

7. The lipid particle of claim 6 , wherein the nucleic acid is an siRNA.

8. A pharmaceutical composition comprising a lipid particle of claim 4 and a pharmaceutically acceptable excipient, carrier, or diluent.

9. The lipid particle of claim 5 , wherein the nucleic acid is mRNA.

10. The lipid of claim 1 , or a salt or isomer thereof, wherein X and Y are each independently —O—.

11. The lipid of claim 1 , or a salt or isomer thereof, wherein R 1 and R 2 are each independently for each occurrence optionally substituted C 10 -C 30 alkoxy, optionally substituted C 10 -C 30 alkenyl, optionally substituted C 10 -C 30 alkenyloxy, optionally substituted C 10 -C 30 alkynyl, optionally substituted C 10 -C 30 alkynyloxy, or optionally substituted C 10 -C 30 acyl.

12. The lipid of claim 11 , or a salt or isomer thereof, wherein R 1 and R 2 are each independently for each occurrence optionally substituted C 10 -C 30 alkenyl.

13. The lipid of claim 11 , or a salt or isomer thereof, wherein R 1 and R 2 are each independently for each occurrence optionally substituted C 10 -C 30 alkynyl.

14. The lipid of claim 1 , or a salt or isomer thereof, wherein A 1 , and A 2 are each independently —O—.

15. The lipid of claim 1 , or a salt or isomer thereof, wherein A 1 , and A 2 are each independently —CH 2 —.

16. The lipid of claim 1 , or a salt or isomer thereof, wherein Z is N.

17. The lipid of claim 1 , or a salt or isomer thereof, wherein Z is C(R 3 ).

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Jul 27, 2018
From: PROTIVA BIOTHERAPEUTICS INC.; ARBUTUS BIOPHARMA CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 046640/0764 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2017
From: MANOHARAN, MUTHIAH; RAJEEV, KALLANTHOTTATHIL G.; BUTLER, DAVID; NAIR, JAYAPRAKASH K.; JAYARAMAN, MUTHUSAMY; ELTEPU, LAXMAN
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 043533/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2017
From: ALNYLAM PHARMACEUTICALS, INC.
To: TEKMIRA PHARMACEUTICALS CORPORATION
Reel/Frame 043534/0129 →
CHANGE OF NAME Recorded Sep 8, 2017
From: TEKMIRA PHARMACEUTICALS CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 043534/0262 →
Continuity (9)
Continuation 14953677 · Nov 30, 2015
Continuation 13128253
Provisional Application 61113179 · Nov 10, 2008
Provisional Application 61154350 · Feb 20, 2009
Provisional Application 61171439 · Apr 21, 2009
Provisional Application 61185438 · Jun 9, 2009
Provisional Application 61225898 · Jul 15, 2009
Provisional Application 61234098 · Aug 14, 2009
Related Publication 20180125985A1 · May 10, 2018